APA (7th ed.) Citation

Bendell, J., LoRusso, P., Overman, M., Noonan, A. M., Kim, D., Strickler, J. H., . . . Patel, S. P. (2023). First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 72(7), 2443-2458. https://doi.org/10.1007/s00262-023-03430-6

Chicago Style (17th ed.) Citation

Bendell, Johanna, et al. "First-in-human Study of Oleclumab, a Potent, Selective Anti-CD73 Monoclonal Antibody, Alone or in Combination with Durvalumab in Patients with Advanced Solid Tumors." Cancer Immunology, Immunotherapy 72, no. 7 (2023): 2443-2458. https://doi.org/10.1007/s00262-023-03430-6.

MLA (9th ed.) Citation

Bendell, Johanna, et al. "First-in-human Study of Oleclumab, a Potent, Selective Anti-CD73 Monoclonal Antibody, Alone or in Combination with Durvalumab in Patients with Advanced Solid Tumors." Cancer Immunology, Immunotherapy, vol. 72, no. 7, 2023, pp. 2443-2458, https://doi.org/10.1007/s00262-023-03430-6.